Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Repeated measures ANOVA showed both treatment and placebo decreased BMI (F(5,18) = 6.55; p = 0.0001), ALT (F(5,18) = 4.34; p = 0.0003), Triglycerides (F(5,19) = 10.1; p = 0.0001), insulin-‘120 (F(5,19) = 2.97; p = 0.015) and vitamin D (F(5,18) = 16; p<0.0001).

Source: Effects on anthropometric, clinical and laboratory parameters. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Human research reported

Reported blinded roles: participants, investigators.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.

Source: Abstract.

Patients were recruited and studied between March 2014 and April 2015.

Source: Methods.

Participants and investigators were blinded to the treatment for the duration of the study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial

Study design awaiting verification · PLoS ONE · 2016

Original publication title

Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial

Claudia Della Corte; Guido Carpino; Rita De Vito; Cristiano De Stefanis; Anna Alisi; Stefano Cianfarani; Diletta Overi; Antonella Mosca; Laura Stronati; Salvatore Cucchiara; Massimiliano Raponi; Eugenio Gaudio; Christopher D. Byrne; Valerio Nobili

© 2016 Della Corte et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has potential antifibrotic properties in liver disease.

Source: Background

Abstract: What methods does the paper describe?

The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome was amelioration of metabolic parameters.

Source: Methods

Abstract: Trial Design

To date, however, there are no studies that have tested the combination of Docosahexanoic acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.

Source: Trial Design

Abstract: Results

DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment.

Source: Results

Abstract: Conclusion

DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment.

Source: Conclusion
Authors’ abstract

Background

There are no licensed treatments for non alcoholic fatty liver disease (NAFLD) in adults or children. In NAFLD, several studies have shown a benefit of omega-3 fatty acid treatment on lipid profile, insulin-sensitivity and hepatic steatosis and it has also been suggested that Vitamin D treatment has potential antifibrotic properties in liver disease.

Trial Design

To date, however, there are no studies that have tested the combination of Docosahexanoic acid (DHA) and vitamin D treatment which may benefit the whole spectrum of disease in NAFLD. Our aim therefore, was to test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trial.

Methods

The 41/43 patients completed the study (18-treatment, 23-placebo). At 12 months: i) the main outcome was liver histology improvement, defined by NAS; ii) the secondary outcome was amelioration of metabolic parameters.

Results

DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p<0.001 for baseline versus end of study). There was no change in fibrosis score, but a reduction of the activation of hepatic stellate cells (HSC) and fibrillar collagen content was noted (3.51±1.66 v. 1.59±1.37; p = 0.003) in treatment group. Moreover, the triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment.

Conclusion

DHA plus vitamin D treatment improved insulin-resistance, lipid profile, ALT and NAS. There was also decreased HSC activation and collagen content with treatment.

Publication and source details

Original title: Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial

Claudia Della Corte; Guido Carpino; Rita De Vito; Cristiano De Stefanis; Anna Alisi; Stefano Cianfarani; Diletta Overi; Antonella Mosca; Laura Stronati; Salvatore Cucchiara; Massimiliano Raponi; Eugenio Gaudio; Christopher D. Byrne; Valerio Nobili

PLoS ONE · 2016

Competing Interests: The authors have declared that no competing interests exist.

  • Conceptualization: VN, CDC, CDB, GC, EG.

  • Formal analysis: AM, CDB, AL, MR.

  • Investigation: AL, RDV, GC, DO, EG, VN.

  • Methodology: AL, AM, CDS, LS, SC.

  • Resources: CDC, VN.

  • Supervision: CDB, VN, CDC; GC.

  • Validation: AL, RDV, DO, SC,.

  • Writing: original draft: CDC, GC, VN, CDB,.

  • Writing: review & editing: EG, SC, LS.

* E-mail: nobili66@yahoo.it
© 2016 Della Corte et al2016Della Corte et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/501100003196Ministero della SaluteRicerca Corrente 2016Nobili Valerio VN is supported by the Italian Ministry of Health funds (Fondi di Ricerca Corrente 2016).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T06:01:35.358777+00:00

DOI: 10.1371/journal.pone.0168216 · PMC5158039